Kyung Min Jo

Title: Kyung Min Jo and Pneumococcal Vaccine Innovation.

Introduction

Kyung Min Jo is an inventor associated with Celltrion Inc. in Incheon, South Korea. His listed patent work concerns a multivalent immunogenic composition designed to broaden protection against pneumococcal serotypes.

Latest Patents

Jo is credited with 1 patent: “Immunogenic Composition Comprising Multivalent Polysaccharide-Protein Conjugates.” The invention describes a composition containing pneumococcal capsular polysaccharides from multiple serotypes, each conjugated to a carrier protein. It combines serotypes included in conventional vaccines with additional serotypes, including 10A, 11A, 12F, 15B, 22F, 23A, and 35B. The patent describes the composition as intended to induce immune responses across a wider range of serotypes than Prevenar 13, with the goal of supporting broader coverage in regions including Asia, Europe, and North America. Its proposed use is to help prevent pneumococcal diseases in infants, children, and adults.

Career Highlights

Jo’s listed innovation reflects work in vaccine composition and the design of polysaccharide-protein conjugates. His patent is associated with Celltrion Inc., a company based in South Korea.

Collaborations

Pan Kyeom Kim and Wan Geun La are identified as Jo’s coworkers. The available information does not specify their roles in the patent or the nature of their collaboration.

Conclusion

Kyung Min Jo’s listed patent focuses on a multivalent pneumococcal vaccine composition intended to expand serotype coverage, highlighting his contribution to vaccine-related innovation at Celltrion Inc.